Information Provided By: 
Fly News Breaks for March 13, 2018
ATRC
Mar 13, 2018 | 18:35 EDT
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and a $24 price target on AtriCure after hosing investor meetings with the company CFO. O'Brien says AtriCure is performing well amid "newer association guidelines and missionary work from the company", while its MIS business should support revenues this year. The analyst adds that progress on Converge study is also being made, with combined impact of these products leading to accelerated growth rates for AtriCure in 2020.
News For ATRC From the Last 2 Days
ATRC
Apr 23, 2024 | 07:36 EDT
ATRC
Apr 23, 2024 | 06:16 EDT
Oppenheimer analyst Suraj Kalia upgraded AtriCure to Outperform from Perform with a $32 price target.
